EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration

Satya Das iD, Shannon S Stockton, Saamir A Hassan

The Oncologist · 05.07.2023 · 28 (7) · 575-583

DOI: 10.1093/oncolo/oyad126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 20.05.2023. Verfasst von Satya Das und 2 weiteren Autor:innen. Beteiligte Einrichtung: Late Development Oncology, GI, AstraZeneca, Gaithersburg, MD, USA. Hauptthemen laut MEDLINE: Carcinoid Heart Disease, Carcinoid Tumor, Malignant Carcinoid Syndrome, Neuroendocrine Tumors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carcinoid heart disease (CaHD) is an important complication among patients with metastatic neuroendocrine tumors and carcinoid syndrome (CS). CS patients (25%-65%) eventually develop CaHD; these patients face a significantly increased risk of morbidity and mortality. Guidance papers (eg, clinical practice guidelines, consensus guidelines, and expert statements) have been established by major organizations across the disciplines of cardiology and oncology; however, these recommendations are not routinely implemented. The aim of this article is to encourage the integration of current recommendations from national societies into clinical practice. Early screening upon recognition of CS and prior to the development of CaHD symptoms is paramount, as no existing therapies are approved to reverse the fibrotic damage to the heart once it occurs. Valvular replacement is the only definitive treatment for CaHD once it has developed. When patients are noted to have urinary 5-hydroxyindoleacetic acid (5-HIAA) levels ≥300 µmol/24 h and/or serum N-terminal pro B-type natriuretic peptide (NT-proBNP) levels >260 pg/mL, echocardiography is recommended. Systemic approaches to control tumor growth and hormonal secretion include somatostatin analogs (SSAs), followed by options including peptide receptor radiotherapy (PRRT), everolimus and liver embolization. Telotristat is the primary choice for control of diarrhea refractory to SSA. Diuretics are the mainstay of heart failure symptom management for patients who develop CaHD. Considerations for future research are discussed, including the ongoing TELEHEART (TELotristat Ethyl in a HEART biomarker study) trial involving telotristat and not yet activated CHARRT (Carcinoid Heart disease And peptide Receptor Radiotargetted Therapy) study involving PRRT with lutetium 177 (177Lu) dotatate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoid Heart DiseaseCarcinoid TumorMalignant Carcinoid SyndromeNeuroendocrine TumorsHumansEverolimus

Stichwörter der Autor:innen

5-hydroxyindoleacetic acidN-terminal pro B-type natriuretic peptidecarcinoid heart diseasecarcinoid syndromeneuroendocrine tumors

Substanzen

Everolimus

Autor:innen und Institutionen

  • Late Development Oncology, GI, AstraZeneca, Gaithersburg, MD, USA.
  • Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Ascension Texas Cardiovascular, Cedar Park, TX, USA.

ORCID-Profile: Satya Das

Zitieren

APA

Das, S., Stockton, S. S., & Hassan, S. A. (2023). Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration. The Oncologist, 28(7), 575-583. https://doi.org/10.1093/oncolo/oyad126

Vancouver

Das S, Stockton SS, Hassan SA. Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration. The Oncologist. 2023;28(7):575-583. doi:10.1093/oncolo/oyad126

BibTeX
@article{Das2023,
  author = {Das, Satya and Stockton, Shannon S and Hassan, Saamir A},
  title = {Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {7},
  pages = {575--583},
  doi = {10.1093/oncolo/oyad126}
}
Kostenlos starten →